Medical device firm CloudCath has secured approval from the US Food and Drug Administration (FDA) for its novel peritoneal dialysis (PD) at-home patient monitoring system.

CloudCath system is claimed to be the world’s first data-driven and cloud-based remote monitoring platform for PD patients.

With an advanced technology that integrates into the patient’s daily PD protocol, the CloudCath system is said to deliver continuous analytics from the patient’s home.

By delivering real-time notifications to both clinicians and patients, the CloudCath PD monitoring platform enables the patient monitoring of dialysate fluid needed for safe home use of PD.

According to the company, early data demonstrate patients and clinicians may be informed to the need for evaluation days before the onset of symptoms, helping to take early medical intervention, diagnosis, and treatment.

CloudCath CEO and co-founder Aly ElBadry said: “With the 2019 Executive Order calling for increased use of at-home dialysis, CloudCath’s automated sensing and advanced PD care algorithm build a stronger connection between clinicians and patients to help dialysis providers meet these goals.

“We are excited to deliver new health insights and care algorithms that aim to eventually reduce hospitalizations and improve quality of life for PD patients.”

CloudCath’s new patient monitoring system is expected to see a limited roll out in the coming months with several clinics in targeted regions of the US.

In February 2020, CloudCath secured a $12m in series A financing to commercialise its at-home peritoneal dialysis device.

Using biologic insights, machine learning algorithms, and remote monitoring IoT technologies, CloudCath solutions deliver automated health analytics from human fluid assessment to healthcare providers.